EOLS250117P10000
- 0.20
- 0.000.00%
Evolus Newsroom
Fewer Investors Than Expected Jumping On Evolus, Inc. (NASDAQ:EOLS)
Evolus, Inc.'s (NASDAQ:EOLS) Path To Profitability
Analysts Offer Insights on Healthcare Companies: Evolus (EOLS), Ultragenyx Pharmaceutical (RARE) and Henry Schein (HSIC)
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Evolus (NASDAQ:EOLS) Is Carrying A Fair Bit Of Debt
US Manufacturing Index Rises To 43, Highest Since 2020
Down -29.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Evolus (EOLS)
Insiders At Evolus Sold US$5.6m In Stock, Alluding To Potential Weakness
Earnings Update: Evolus, Inc. (NASDAQ:EOLS) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
Mizuho Securities Maintains Evolus(EOLS.US) With Buy Rating
A Quick Look at Today's Ratings for Evolus(EOLS.US), With a Forecast Between $20 to $27
Analysts Conflicted on These Healthcare Names: Moderna (MRNA), Poseida Therapeutics (PSTX) and Evolus (EOLS)
Evolus Third Quarter 2024 Earnings: Misses Expectations
Evolus Down Over 11%, on Pace for Largest Percent Decrease Since August 2022 -- Data Talk
Needham Maintains Evolus(EOLS.US) With Buy Rating, Maintains Target Price $22
Evolus Maintains Strong Growth Outlook Despite Earnings Miss: A Buy Recommendation
HC Wainwright & Co. Reiterates Buy on Evolus, Maintains $27 Price Target
Evolus Inc (EOLS) Q3 2024 Earnings Call Highlights: Revenue Surge Amid Market Challenges
Evolus, Inc. (EOLS) Q3 2024 Earnings Conference Call Transcript Summary